arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Xenetic Biosciences, Inc.

XBIO
$3.06 ▲ +0.15 (+5.15%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
61 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

Xenetic Biosciences, Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $7.0M
Dividend Yield
Revenue Growth 36.0%
Op. Margin -62.2%
ROIC -5.7%
FCF / Share $-0.23
Trailing P/E
Price / Book 1.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

61-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$806.92K
↑ +36.0%
Net Income Profit after all expenses
$-456.38K
↑ +49.5%
Operating Margin Operating profit as % of sales
-62.2%
↑ +23.5% 2th
FCF / Share Free cash flow per share
$-0.23
↑ +64.0%
Long-Term Debt Long-term obligations
$212.81K
— 0.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
3
Returns
20
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 61 quarters